European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“Big news from EORTC!
We’re excited to share that the PEACE III trial has reached its final overall survival results. A major milestone in prostate cancer research.
The final analysis confirms that adding radium-223 to enzalutamide significantly improves survival for patients with metastatic castration-resistant prostate cancer.
This is an important step forward in making treatments more effective and tailored for patients.
A big thank you to all the collaborators, investigators, and especially the patients who made this possible.
More from European Organisation for Research and Treatment of Cancer on OncoDaily.